IL22 and metabolic dysfunction-associated steatotic liver disease: These protective metabolic effects of IL-22 were demonstrated upon administration of exogenous IL-22 or in IL-22 Tg mice, rather than being associated with endogenous levels of the cytokine which are usually low in circulation and livers of HFD-induced MASLD (232, 233, 237).